SENSTROKENCT07510919
CGM in Acute Ischemic Stroke
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 6 more changesShow less
- Primary endpoints: details revised at 1 of 1 entry
- Eligibility criteria expanded, about 5 words
- Study sites: 0 to 2
- Start date changed from estimate of Apr 2026 to Apr 21, 2026
- Secondary endpoints: details revised at 5 of 9 entries
- Collaborators expanded, about 3 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
Participants receive glucose monitoring using a continuous glucose monitoring (CGM) system (FreeStyle Libre 2). Glucose management during hospitalization is guided by CGM measurements and used for treatment decisions according to the hospital glucose management protocol.
Participants receive standard glucose monitoring using intermittent point-of-care testing (POCT) with capillary finger-prick measurements. Glucose management during hospitalization follows the hospital glucose management protocol based on POCT values. A blinded continuous glucose monitoring sensor (FreeStyle Libre Pro iQ) is placed for data collection purposes only. CGM data are not available to the clinical team and are not used for treatment decisions.
Devices: Continuous Glucose Monitoring
Diagnostic tests: Point-of-Care Testing
Sites
2 sites in 1 country